Q4 2024 · 13F-HR
DCVC Opportunity Fund II GP, LLCholdings as filed
Filed 2025-02-14 · accession 0001104659-25-013461
$113.0M
Reported value
2
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 773122106 | — | Rocket Lab USA, Inc. | $86.3M | 76.4% | 3,388,249 | Common | SOLE |
| 75629V104 | RXRX | Recursion Pharmaceuticals, Inc. | $26.7M | 23.6% | 3,951,141 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.